MX2020003369A - Enantiomeros de tiazoles sustituidos como compuestos antivirales. - Google Patents
Enantiomeros de tiazoles sustituidos como compuestos antivirales.Info
- Publication number
- MX2020003369A MX2020003369A MX2020003369A MX2020003369A MX2020003369A MX 2020003369 A MX2020003369 A MX 2020003369A MX 2020003369 A MX2020003369 A MX 2020003369A MX 2020003369 A MX2020003369 A MX 2020003369A MX 2020003369 A MX2020003369 A MX 2020003369A
- Authority
- MX
- Mexico
- Prior art keywords
- enantiomers
- antiviral compounds
- substituted thiazoles
- antiviral
- medicaments
- Prior art date
Links
- 230000000840 anti-viral effect Effects 0.000 title abstract 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 150000003557 thiazoles Chemical class 0.000 title 1
- 239000003814 drug Substances 0.000 abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/44—Acylated amino or imino radicals
- C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/54—Nitrogen and either oxygen or sulfur atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se refiere a nuevos compuestos antivirales con estereoconfiguración específica, especialmente a nuevos enantiómeros específicos, a un proceso para su preparación y a su uso como medicamentos, en particular como medicamentos antivirales.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17195047 | 2017-10-05 | ||
| PCT/EP2018/077022 WO2019068817A1 (en) | 2017-10-05 | 2018-10-04 | SUBSTITUTED THIAZOLEAN ENANTIOMERS AS ANTIVIRAL COMPOUNDS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020003369A true MX2020003369A (es) | 2020-07-29 |
Family
ID=60022026
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020003369A MX2020003369A (es) | 2017-10-05 | 2018-10-04 | Enantiomeros de tiazoles sustituidos como compuestos antivirales. |
Country Status (37)
| Country | Link |
|---|---|
| US (3) | US11278534B2 (es) |
| EP (2) | EP3692039B1 (es) |
| JP (1) | JP7215689B2 (es) |
| KR (1) | KR102708082B1 (es) |
| CN (1) | CN111433203B (es) |
| AR (1) | AR113344A1 (es) |
| AU (1) | AU2018344471B2 (es) |
| CA (1) | CA3077397A1 (es) |
| CL (1) | CL2020000869A1 (es) |
| CR (1) | CR20200154A (es) |
| DK (1) | DK3692039T3 (es) |
| EA (1) | EA202090620A1 (es) |
| EC (1) | ECSP20021132A (es) |
| ES (1) | ES2939652T3 (es) |
| FI (1) | FI3692039T3 (es) |
| HR (1) | HRP20230158T1 (es) |
| HU (1) | HUE061307T2 (es) |
| IL (1) | IL273681B2 (es) |
| JO (1) | JOP20200110B1 (es) |
| LT (1) | LT3692039T (es) |
| MA (1) | MA50609B1 (es) |
| MD (1) | MD3692039T2 (es) |
| MX (1) | MX2020003369A (es) |
| MY (1) | MY202544A (es) |
| NI (1) | NI202000025A (es) |
| PH (1) | PH12020550132A1 (es) |
| PL (1) | PL3692039T3 (es) |
| PT (1) | PT3692039T (es) |
| RS (1) | RS64000B1 (es) |
| SG (1) | SG11202002420SA (es) |
| SI (1) | SI3692039T1 (es) |
| SM (1) | SMT202300080T1 (es) |
| TW (1) | TWI706941B (es) |
| UA (1) | UA126163C2 (es) |
| UY (1) | UY37917A (es) |
| WO (1) | WO2019068817A1 (es) |
| ZA (1) | ZA202002150B (es) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019068817A1 (en) * | 2017-10-05 | 2019-04-11 | Innovative Molecules Gmbh | SUBSTITUTED THIAZOLEAN ENANTIOMERS AS ANTIVIRAL COMPOUNDS |
| WO2019168874A1 (en) | 2018-02-27 | 2019-09-06 | The Research Foundation For The State University Of New York | Difluoromethoxylation and trifluoromethoxylation compositions and methods for synthesizing same |
| TW202038947A (zh) | 2018-11-28 | 2020-11-01 | 德商創新分子有限責任公司 | 在與溶瘤病毒之組合療法中治療癌症的解旋酶引子酶抑制劑 |
| KR20230131177A (ko) | 2020-10-29 | 2023-09-12 | 이노베이티브 몰리큘스 게엠베하 | 항바이러스 화합물로서 중수소화된 아미노티아졸 화합물 |
| EP4466255A1 (en) | 2022-01-17 | 2024-11-27 | Innovative Molecules GmbH | Solid crystalline forms of helicase-primase inhibitors and process of preparation thereof |
| IL319024A (en) | 2022-08-29 | 2025-04-01 | Assembly Biosciences Inc | Pharmaceutical preparations for the herpes virus |
| EP4581029A1 (en) | 2022-08-29 | 2025-07-09 | Assembly Biosciences, Inc. | Cyclic urea thiazolyl compounds for treatment of hsv |
| WO2025017032A1 (en) | 2023-07-17 | 2025-01-23 | Innovative Molecules Gmbh | Micronized crystalline hydrochloride salts of antiviral helicase-primase inhibitor compounds |
| WO2025111598A1 (en) | 2023-11-22 | 2025-05-30 | Assembly Biosciences, Inc. | Azetidine compounds for treatment of hsv |
| US20260014154A1 (en) | 2024-07-12 | 2026-01-15 | Assembly Biosciences, Inc. | Cyclic urea thiazolyl compound for treatment of viral infections unresponsive to treatment with a first antiviral therapy |
| US20260042748A1 (en) | 2024-08-07 | 2026-02-12 | Assembly Biosciences, Inc. | Azetidine compounds for treatment of hsv |
| US20260042767A1 (en) | 2024-08-07 | 2026-02-12 | Assembly Biosciences, Inc. | Tricyclic compounds for treatment of hsv |
| US20260042766A1 (en) | 2024-08-07 | 2026-02-12 | Assembly Biosciences, Inc. | Tricyclic compounds for treatment of hsv |
| WO2026078039A1 (en) | 2024-10-09 | 2026-04-16 | Innovative Molecules Gmbh | Oral administration forms of antiviral helicase-primase inhibitors |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA984848A (en) | 1970-01-16 | 1976-03-02 | Kurt H. Pilgram | Herbicides |
| ES2186811T3 (es) | 1995-12-29 | 2003-05-16 | Boehringer Ingelheim Pharma | Derivados de feniltiazol con propiedades anti-virus herpes. |
| US6040321A (en) * | 1997-11-12 | 2000-03-21 | Bristol-Myers Squibb Company | Aminothiazole inhibitors of cyclin dependent kinases |
| AU3289299A (en) | 1998-02-19 | 1999-09-06 | Tularik Inc. | Antiviral agents |
| NZ507032A (en) | 1998-03-19 | 2003-06-30 | Pharmacia & Upjohn | 1,3,4-thiadiazoles useful for the treatment of herpes and cytomegalovirus infections |
| WO2000053591A1 (de) | 1999-03-08 | 2000-09-14 | Bayer Aktiengesellschaft | Thiazolylharnstoff-derivate und ihre verwendung als antivirale mittel |
| DE19959958A1 (de) | 1999-12-13 | 2001-08-30 | Bayer Ag | Thiazolylharnstoff-Derivate |
| DE19927415A1 (de) | 1999-06-16 | 2000-12-21 | Bayer Ag | Indolinylharnstoffderivate |
| DOP2000000109A (es) * | 1999-12-23 | 2002-08-30 | Gerald Kleymann | Derivados de tiazolilamida |
| DE10039265A1 (de) | 2000-08-11 | 2002-02-21 | Bayer Ag | Thiazolylamid-Derivate |
| EP1319185A1 (en) | 2000-06-15 | 2003-06-18 | Bayer Aktiengesellschaft | Method for identifying compounds with anti-herpes activity |
| DE10038022A1 (de) | 2000-08-04 | 2002-02-14 | Bayer Ag | Inverse Thiazolylamid-Derivate |
| DE10044328A1 (de) | 2000-09-07 | 2002-03-21 | Bayer Ag | Thiazolylcarbonyl-Derivate |
| DE10044358A1 (de) | 2000-09-07 | 2002-03-21 | Bayer Ag | Thiazolylcarbonylheterocyclyl-Derivate |
| DE10044353A1 (de) | 2000-09-07 | 2002-04-04 | Bayer Ag | Unkompetitive Inhibitoren der Helikase-Primase |
| DE10129714A1 (de) | 2001-06-22 | 2003-01-02 | Bayer Ag | Topische Anwendung von Thiazolylamiden |
| DE10129716A1 (de) | 2001-06-22 | 2003-01-02 | Bayer Ag | Kombinationspräparate zur Herpes-Behandlung |
| DE10129715A1 (de) | 2001-06-22 | 2003-01-02 | Bayer Ag | Thiazolylamide |
| DE10129717A1 (de) | 2001-06-22 | 2003-01-02 | Bayer Ag | Kombinationspräparate zur Herpes-Behandlung |
| DE10131128A1 (de) | 2001-06-28 | 2003-01-16 | Bayer Ag | Sekundäre Sulfonamide |
| DE10210319A1 (de) | 2002-03-08 | 2003-09-18 | Bayer Ag | Thiazolylcarbonyl-Derivate |
| DE10235967B4 (de) | 2002-08-06 | 2005-09-08 | Bayer Healthcare Ag | Methode zum Identifizieren von Substanzen mit antimikrobieller Wirkung |
| DE10300109A1 (de) | 2003-01-07 | 2004-07-15 | Bayer Healthcare Ag | Methode zur Inhibition der Replikation von Herpesviren |
| BRPI0507278A (pt) | 2004-01-30 | 2007-06-26 | Vertex Pharma | moduladores dos transportadores do cassete de ligação ao atp |
| DE102005014248A1 (de) | 2005-03-30 | 2006-10-05 | Aicuris Gmbh & Co. Kg | Pharmazeutische Zubereitung von N-[5-(Aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamid |
| WO2008067839A1 (en) | 2006-12-08 | 2008-06-12 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Dry electrode cap for electro-encephalography |
| DE102010046720A1 (de) | 2010-09-23 | 2012-03-29 | Bayer Schering Pharma Aktiengesellschaft | Verfahren zur Herstellung von pan-CDK-Inhibitoren der Formel (l), sowie Intermediate der Herstellung |
| CN103269593A (zh) * | 2010-11-01 | 2013-08-28 | 罗马克实验室有限公司 | 烷基亚磺酰基取代的噻唑化物化合物 |
| TW201636330A (zh) | 2011-05-24 | 2016-10-16 | 拜耳知識產權公司 | 含有硫醯亞胺基團之４－芳基－ｎ－苯基－１，３，５－三氮雜苯－２－胺 |
| EP2573086A1 (en) | 2011-09-26 | 2013-03-27 | AiCuris GmbH & Co. KG | N-[5-(Aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mesylate monohydrate |
| JP6918823B2 (ja) * | 2016-04-06 | 2021-08-11 | イノベーティブ モレキュールズ ゲーエムベーハーＩｎｎｏｖａｔｉｖｅ Ｍｏｌｅｃｕｌｅｓ Ｇｍｂｈ | 抗ウイルス剤として有用なアミノチアゾール誘導体 |
| AR110250A1 (es) | 2016-11-28 | 2019-03-13 | Aicuris Anti Infective Cures Gmbh | Formulación tópica que comprende n-[5-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)-fenil]-acetamida |
| AR110251A1 (es) | 2016-11-28 | 2019-03-13 | Aicuris Anti Infective Cures Gmbh | Una sal maleato de la base libre de n-[5-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)-fenil]-acetamida, formulaciones farmacéuticas, métodos de fabricación y usos de la misma |
| LT3544976T (lt) | 2016-11-28 | 2021-08-10 | Aicuris Gmbh & Co. Kg | N-[5-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)-fenil]-acetamido laisvos bazės hemihidratas, jo gamybos būdai ir panaudojimai |
| US10647710B2 (en) | 2017-01-09 | 2020-05-12 | Medshine Discovery Inc. | Thiazole derivative and applications thereof |
| WO2019068817A1 (en) * | 2017-10-05 | 2019-04-11 | Innovative Molecules Gmbh | SUBSTITUTED THIAZOLEAN ENANTIOMERS AS ANTIVIRAL COMPOUNDS |
-
2018
- 2018-10-04 WO PCT/EP2018/077022 patent/WO2019068817A1/en not_active Ceased
- 2018-10-04 HR HRP20230158TT patent/HRP20230158T1/hr unknown
- 2018-10-04 CN CN201880065255.2A patent/CN111433203B/zh active Active
- 2018-10-04 CR CR20200154A patent/CR20200154A/es unknown
- 2018-10-04 MA MA50609A patent/MA50609B1/fr unknown
- 2018-10-04 MD MDE20200816T patent/MD3692039T2/ro unknown
- 2018-10-04 FI FIEP18779696.6T patent/FI3692039T3/fi active
- 2018-10-04 EP EP18779696.6A patent/EP3692039B1/en active Active
- 2018-10-04 SG SG11202002420SA patent/SG11202002420SA/en unknown
- 2018-10-04 ES ES18779696T patent/ES2939652T3/es active Active
- 2018-10-04 IL IL273681A patent/IL273681B2/en unknown
- 2018-10-04 JP JP2020519403A patent/JP7215689B2/ja active Active
- 2018-10-04 TW TW107135101A patent/TWI706941B/zh active
- 2018-10-04 AR ARP180102864A patent/AR113344A1/es unknown
- 2018-10-04 EA EA202090620A patent/EA202090620A1/ru unknown
- 2018-10-04 SM SM20230080T patent/SMT202300080T1/it unknown
- 2018-10-04 SI SI201830861T patent/SI3692039T1/sl unknown
- 2018-10-04 PT PT187796966T patent/PT3692039T/pt unknown
- 2018-10-04 MY MYPI2020001322A patent/MY202544A/en unknown
- 2018-10-04 UA UAA202002635A patent/UA126163C2/uk unknown
- 2018-10-04 UY UY0001037917A patent/UY37917A/es active IP Right Grant
- 2018-10-04 CA CA3077397A patent/CA3077397A1/en active Pending
- 2018-10-04 HU HUE18779696A patent/HUE061307T2/hu unknown
- 2018-10-04 KR KR1020207009294A patent/KR102708082B1/ko active Active
- 2018-10-04 LT LTEPPCT/EP2018/077022T patent/LT3692039T/lt unknown
- 2018-10-04 US US16/753,814 patent/US11278534B2/en active Active
- 2018-10-04 EP EP22213253.2A patent/EP4209491A1/en active Pending
- 2018-10-04 MX MX2020003369A patent/MX2020003369A/es unknown
- 2018-10-04 AU AU2018344471A patent/AU2018344471B2/en active Active
- 2018-10-04 PL PL18779696.6T patent/PL3692039T3/pl unknown
- 2018-10-04 DK DK18779696.6T patent/DK3692039T3/da active
- 2018-10-04 RS RS20230156A patent/RS64000B1/sr unknown
-
2020
- 2020-03-25 PH PH12020550132A patent/PH12020550132A1/en unknown
- 2020-04-01 NI NI202000025A patent/NI202000025A/es unknown
- 2020-04-01 CL CL2020000869A patent/CL2020000869A1/es unknown
- 2020-04-03 EC ECSENADI202021132A patent/ECSP20021132A/es unknown
- 2020-05-04 ZA ZA2020/02150A patent/ZA202002150B/en unknown
- 2020-05-07 JO JOJO/P/2020/0110A patent/JOP20200110B1/ar active
-
2022
- 2022-01-21 US US17/581,166 patent/US12295945B2/en active Active
-
2024
- 2024-06-06 US US18/736,166 patent/US12527778B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020003369A (es) | Enantiomeros de tiazoles sustituidos como compuestos antivirales. | |
| PH12019550235A1 (en) | Kinase inhibitors and uses thereof | |
| MY188447A (en) | Indazole compounds as fger kinase inhibitor, preparation and use thereof | |
| PH12018501979A1 (en) | Aminothiazole derivatives useful as antiviral agents | |
| AU2015208932A8 (en) | (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase I inhibitors | |
| MX2016016143A (es) | Compuestos de [1,2,4]triazol sustituido. | |
| MX365494B (es) | Procedimiento de compuesto antifungico. | |
| AU2015299431B2 (en) | Pyrrolidinone derivatives as metAP-2 inhibitors | |
| MX369357B (es) | Procedimiento de compuesto antifungico. | |
| JO3372B1 (ar) | مشتقات 5-بنزيل إيزوكينولين لعلاج أمراض القلب والأوعية الدموية | |
| IN2014MU00455A (es) | ||
| NZ742104A (en) | Innovative preparation and crystallization of iosimenol | |
| MX2020012065A (es) | Compuestos de ciclopentano. | |
| MX350122B (es) | Tinturas dispersas, su preparación y su uso. | |
| PH12017501869A1 (en) | (s)-2'-vinyl-abscisic acid derivatives | |
| GB2564185A (en) | Process for the preparation of derivatives of benzodioxole | |
| MY180413A (en) | Process for the decomposition of lignocellulose-containing biomass-material | |
| MX385963B (es) | Procedimiento para la preparacion de 4-amino-1-( (1s, 4r, 5s) -2-fluoro-4,5-dihidroxi-3-hidroximetil-ciclopent-2-enil)-1h-pirimidin-2-ona. | |
| MX2016005222A (es) | Tinturas acidas, proceso para su produccion y su uso. | |
| MX2016005220A (es) | Tinturas acidas, proceso para su produccion y su uso. | |
| ZA202201221B (en) | Cyclopentane compounds | |
| WO2017059318A3 (en) | Scaphopetalone analogs and their uses | |
| LV14852A (lv) | Triazolilpurīna atvasinājumi kā pretvīrusu preparāti | |
| MX2015009114A (es) | Proceso para preparar 5-fluoro-1-metil-3-difluorometil-1h-pirazol- 4-carbaldehido. | |
| MX2016010549A (es) | Indol- y bencimidazolcarboxamidas como insecticidas y acaricidas. |